{
    "pmcid": "10562541",
    "qa_pairs": {
        "What are the two specific regions of the SARS-CoV-2 spike protein targeted by the bispecific antibody K203.A?": [
            "Receptor-binding domain (RBD) and fusion peptide (FP)",
            "N-terminal domain (NTD) and fusion peptide (FP)",
            "Receptor-binding domain (RBD) and S2 subunit",
            "N-terminal domain (NTD) and S1 subunit"
        ],
        "What is the format of the bispecific antibody K203.A, and what mutation is included to ensure stability?": [
            "IgG4-(scFv)2 format with an S228P mutation",
            "IgG1-(scFv)2 format with a D265A mutation",
            "IgG2-(scFv)2 format with a P329G mutation",
            "IgG3-(scFv)2 format with an E233K mutation"
        ],
        "What is the significance of the fusion peptide (FP) as a target for antibody development according to the study?": [
            "It is more conserved across SARS-CoV-2 variants and other betacoronaviruses.",
            "It is highly variable and allows for targeting of multiple viral strains.",
            "It is responsible for the virus's ability to evade immune detection.",
            "It is the primary site for antibody-dependent enhancement (ADE)."
        ],
        "What mutation in the RBD is mentioned as reducing the efficacy of existing neutralizing antibodies?": [
            "E484K mutation",
            "D614G mutation",
            "N501Y mutation",
            "P681R mutation"
        ],
        "Which specific variants of SARS-CoV-2 does K203.A demonstrate superior neutralization efficacy against?": [
            "Beta and Gamma variants",
            "Alpha and Delta variants",
            "Mu and Lambda variants",
            "Omicron and Zeta variants"
        ]
    }
}